Form 144 LIGAND PHARMACEUTICALS Filed by: LAMATTINA JOHN L
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $150.00 to $160.00. They now have an "overweight" rating on the stock.MarketBeat
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $141.00 to $143.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance [Yahoo! Finance]Yahoo! Finance
- Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 GuidanceBusiness Wire
LGND
Earnings
- 11/7/24 - Beat
LGND
Sec Filings
- 12/6/24 - Form 4
- 12/2/24 - Form 4
- 11/14/24 - Form SC
- LGND's page on the SEC website